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Background: Interactions between the immune system and tumors are highly reciprocal
in nature, leading to speculation that tumor recurrence or therapeutic resistance could
be influenced or predicted by immune events that manifest locally, but can be detected
systemically.
Methods: Multi-parameter flow cytometry was used to examine the percentage
and phenotype of natural killer (NK) cells, myeloid-derived suppressor cells (MDSCs),
monocyte subsets and regulatory T (Treg) cells in the peripheral blood of of 85
patients with breast cancer (50 of whom were assessed before and after one cycle
of anthracycline-based chemotherapy), and 23 controls. Transcriptomic profiles of
peripheral blood mononuclear cells (PBMCs) in 23 patients were generated using a
NanoString gene profiling platform.
Results: An increased percentage of immunosuppressive cells such as granulocytic
MDSCs, intermediate CD14++CD16+ monocytes and CD127negCD25highFoxP3+ Treg
cells was observed in patients with breast cancer, especially patients with stage 3 and 4
disease, regardless of ER status. Following neoadjuvant chemotherapy, B cell numbers
decreased significantly, whereas monocyte numbers increased. Although chemotherapy
had no effect on the percentage of Treg, MDSC and NK cells, the expression of
inhibitory receptors CD85j, LIAR and NKG2A and activating receptors NKp30 and
NKp44 on NK cells increased, concomitant with a decreased expression of NKp46
and DNAM-1 activating receptors. Transcriptomic profiling revealed a distinct group of 3
patients in the triple negative breast cancer (TNBC) cohort who expressed high levels of
mRNA encoding genes predominantly involved in inflammation. The analysis of a large
Foulds et al. PBMC Immunome in Breast Cancer
transcriptomic dataset derived from the tumors of patients with TNBC revealed that the
expression of CD163, CXCR4, THBS1 predicted relapse-free survival.
Conclusions: The peripheral blood immunome of patients with breast cancer is
influenced by the presence and stage of cancer, but not by molecular subtypes.
Furthermore, immune profiling coupled with transcriptomic analyses of peripheral blood
cells may identify patients with TNBC that are at risk of relapse after chemotherapy.
Keywords: flow cytometry, breast cancer, nanostring, MDSC, treg, monocytes, NK cells, immune gene signature
INTRODUCTION
Breast cancer accounts for approximately 15% of all cancers and
remains the most common and leading cause of cancer deaths
in European women (1). Despite earlier detection and significant
advances in adjuvant therapy (AT) improving patient outcomes,
disease recurrence continues to occur in up to 2% of patients,
with approximately 11,000 women succumbing to the disease
each year in the UK alone. It is therefore essential that we
better understand the drivers of disease, disease recurrence and
mechanisms underlying therapeutic resistance.
Triple negative breast cancer (TNBC) encompasses a
heterogeneous group of cancers, the treatment of which remains
a challenge due to the absence of targetable molecules such as
estrogen receptor (ER), progesterone receptor (PR), or epidermal
growth factor receptor 2 (HER2). However, the observation
that patients with TNBC showing more than 50% lymphocytic
infiltration in their tumor core, or within the stroma, exhibit a
better prognosis indicates the strong influence of the immune
system on disease outcomes (2). Whether the favorable clinical
outcome observed in this patient subgroup is related to an
inherent ability of the patient to respond to treatment, the quality
of the anti-tumor immune response, the functional orientation of
the cell infiltrate generated, and/or the immunoregulatory nature
of the tumor microenvironment, remains a matter of debate.
Breast cancer does not develop via a single common
pathogenic pathway, but encompasses a group of neoplastic
events and molecular alterations in breast epithelial cells. In
addition to driving the disease, these events can modulate
immune responses and the immune contexture of the tumor
microenvironment. Consequently, the predictive and prognostic
value of tumor infiltrating lymphocytes (TILs) depends on the
breast cancer subtype (3). Specific gene expression profiling
has enabled the classification of breast cancers into distinct
“intrinsic” subtypes (4), with basal-like breast cancers being
subdivided into six molecular subtypes, one of which is
termed “immunomodulatory” TNBC (5). Furthermore, high
intra-tumoral levels of immune-related genes, including those
associated with type I interferon responses, and the presence of
CD8+ cytotoxic T lymphocytes, correlate with improved disease
outcome in patients with ERBB2+ breast cancer and TNBC
(6, 7).
Abbreviations: MDSC(s), myeloid-derived suppressor cell(s); Treg cell(s),
immunoregulatory T cell(s).
Tumors can establish and promote an immunoregulatory
environment / context which can manifest as detectable changes
in the proportion and phenotype of effector and regulatory cell
populations in the tumor and periphery. A variety of immune
cell types play a critical role in contributing to cancer-induced
immune suppression and sustaining cancer progression (8). For
example, there is an increased percentage of immunoregulatory
CD4+CD25highFoxP3+ T (Treg) cells in the blood and tumors of
patients with invasive breast cancer (9). However, it is likely that
the number of Treg cells in the blood underestimates the number
of these cells present within the tumor microenvironment. Treg
cells might also express different activation and chemokine
receptors than their peripheral blood counterparts (10).
Given the reciprocal relationship between tumors and the
immune system, we have determined the percentage and
phenotype of NK cells and immunosuppressive cell types
such as non-conventional and intermediate monocytes, Treg
cells and myeloid-derived suppressor cells (MDSCs) in the
peripheral blood of patients with newly-diagnosed breast cancer
and individuals with no-known disease (controls) using multi-
parameter flow cytometry, to test the hypothesis that their
presence correlates with the intrinsic subtype or with patient
prognosis. Since a proportion of patients with breast cancer in
our cohort received neoadjuvant chemotherapy prior to surgery,
the effect of a single cycle of anthracycline therapy on immune
cell phenotypes was also investigated. We also profiled the
immune gene transcriptome of peripheral blood mononuclear
cells (PBMCs) from a randomly selected subgroup of 24 patients
with luminal-A breast cancer and TNBC using the NanoString
nCounterTM FLEX amplification-free gene expression profiling
platform.
Patients, especially those in stage 3 and 4, exhibited a more
immunosuppressive phenotype compared to control volunteers,
with increased percentage of granulocytic MDSCs, intermediate
CD14++CD16+ monocytes and CD127negCD25highFoxP3+
Treg cells, regardless of ER status. Although neoadjuvant
chemotherapy had no effect on the percentage of Treg, MDSC
and NK cells, the absolute number of B cells decreased and
the NK cell receptor profile was altered, with an increase in
expression of the inhibitory receptors CD85j, LIAR, and NKG2A
and the activating receptors NKp30 and NKp44 as assessed by
the MFI of the these marker, and coincided with a decrease in the
expression (MFI) of the activating receptors NKp46 and DNAM-
1. Transcriptomic profiling revealed that a distinct group of 3
patients with TNBC expressed high levels of mRNA encoding
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genes predominantly involved in inflammation. The expression
of three of these genes (CD163, CXCR4, THBS1) was found
to predict relapse-free survival in a large, publically-available
transcriptomic dataset generated from the tumors of patients
with TNBC, but not other breast cancer subtypes. It is therefore
possible that TNBC patients with increased risk of relapse as
identified with this new gene-signature would benefit from an
immunotherapeutic intervention prior to chemotherapy.
MATERIALS AND METHODS
Patient Cohort
Two cohorts of individuals were retrospectively studied. One
study cohort was defined as “no-known disease” (ND) controls
(23 women). The other group comprised patients with breast
cancer (n = 90), the demographics of which are provided
in Table 1 and Supplementary Table 1. Informed consent was
obtained from all patients and controls, as per local clinical
practice. The study was approved by the Institutional Review
Board or Independent Ethics Committee and the Hospital
Research and Innovations Department at the participating
sites. Those patients who received chemotherapy had a sample
of blood taken before and 3 weeks after receiving their
first chemotherapeutic cycle which consisted of 500 mg/m2
5-fluorouracil, 75–100 mg/m2 epirubicin and 500 mg/m2
cyclophosphamide.
Blood Collection and Processing
Peripheral blood (5–20ml) was collected by venipuncture into
EDTA-coated VacutainerTM tubes and processed within 2 h.
TABLE 1 | Demographics of patients and healthy (no-disease) controls.
Cancer patients
(Pre-neoadjuvant
treatment)
Cancer with
follow up
data (Post
first round of
neoadjuvant
treatment)
Healthy
volunteers
n = 90 50 23
Mean age (years) 55 (28–89) 52.06 (35–73) 49.387 (35–65)
Tumor grade 1 11
2 43
3 36
Tumor stage I 24
II 35
III 10
IV 21
ER status Negative 21
Positive 69
PR status Negative 38
Positive 52
HER2 status Negative 75
Positive 15
Phenotype Luminal A 57
Luminal B 12
TNBC 18
HER2+ 3
An aliquot of whole blood was used to measure absolute cell
counts using BD TrucountTM beads (BD Biosciences; Mountain
View, CA), as per the manufacturer’s protocol. Briefly, 100
µL of blood was mixed directly in the BD TrucountTM bead
tube and T cell populations, B cells and NK cells were
identified using fluorescently-conjugated monoclonal antibodies
to CD3, CD8, CD19, CD56, CD14, CD4 and CD45 (details in
Supplementary Table 2). Samples were incubated for 15min at
room temperature, protected from the light, and erythrocytes
were lysed using BD Pharm LyseTM (BD Biosciences, 15-min
incubation at room temperature). Cells were analyzed by flow
cytometry within 1 h.
From the remaining blood, peripheral blood mononuclear
cells (PBMCs) were isolated using Ficoll (Greiner Bio-One
Ltd, Stonehouse, UK), as per the manufacturer’s instructions.
Harvested cells were washed twice in phosphate buffered saline
(PBS) and viable cells counted using a haemocytometer or
ChemoMetec NC250TM cell counter. Freshly isolated PBMCs
(2 × 106) were stained using fluorescently-labeled monoclonal
antibodies (mAbs) to CD33, HLA-DR, Lineage Cocktail (CD3,
CD14, CD19, CD20, CD56), CD11b, CD15, Arginase-1 and
CD14 (details in Supplementary Table 2), and the remaining
cells were frozen in liquid nitrogen at a density of 107 cells/mL
in 90% v/v fetal bovine serum (FBS, Fisher Scientific) and 10%
v/v DMSO (Sigma-Aldrich UK, now Merck) for later analysis.
Immunophenotypic Staining of Peripheral
Blood Mononuclear Cells (PBMCs)
PBMCs were rapidly defrosted and suspended in 10mL of
warmed CTL
TM
thaw solution (45mL RPMI 1640 medium, 5mL
CTLTM wash supplement [CTL-Europe GmbH, Bonn, Germany]
and 10 µL benzonase), centrifuged (400 g, 5min) and re-
suspended in 2mL of CTL
TM
wash solution (45mL RPMI 1640
medium and 5mL CTLTM wash supplement). After counting,
cells were rested in the incubator for 1–2 h at 37◦C.
Frozen and thawed PBMCs were used for further analysis
of monocytic MDSCs, Treg cells and NK cells. Any analysis
requiring intracellular staining used 2 × 106 cells, whereas the
analysis of surface markers only used 1× 106 cells.
Cells were washed in PBS and incubated with Human
FcR Blocking Reagent (MACSTM; Miltenyi Biotec) prior to the
addition of antibodies directed against cell surface antigens.
Analysis of the populations was undertaken using appropriate
panels of the following conjugated mAbs: HLA-DR, CD33,
CD15, CD11b, CD33, CD14, HLA-DR, CD16, CD3, CD8 (SK1),
CD19, DNAM1, NKp46, NKp44, NKp30, 2B4, ICOS, CD14,
Lineage Cocktail (CD3, CD14, CD19, CD20, CD56), CD45,
NKG2A, CD3, CD25, CD4, LAIR, CD8, CD85j, CD39, NKG2D,
and CD127 (details in Supplementary Table 2). LIVE/DEADTM
Fixable Violet Dead stain (Invitrogen) was used to exclude non-
viable cells from the analyses.
Analysing the presence of MDSCs and Treg cells
required cells to be subsequently fixed and permeabilized
(Fixation/Permeabilization kit, eBioscience) before staining with
arginase-1 (MDSC staining panel only, R&D Systems) or FoxP3
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mAbs (Treg staining panel only, eBioscience) (antibody details
in Supplementary Table 2).
Once staining was complete, cells were washed in PBS, re-
suspended in Coulter IsotonTM diluent and then analyzed on
a 10-color/3-laser Beckman Coulter GalliosTM flow cytometer
using KaluzaTM v1.3 acquisition and analysis software (Beckman
Coulter).
Gene Expression Profiling
A NanoString nCounterTM FLEX platform (NanoString
Technologies Inc.) was used to determine immune
transcriptomic profiles in PBMCs (11). The nCounterTM analysis
system is a robust and highly reproducible method for detecting
the expression of up to 800 genes in a single reaction with high
sensitivity and linearity across a broad range of expression levels.
The platform is based on digital detection and direct molecular
barcoding of individual target molecules using a unique probe
pair carrying 35- to 50-base target-specific sequences. This
technology allows for direct multiplexed measurements of gene
expression from a low amount of mRNA (25–300 ng) without
the need for amplification by PCR.
For the analysis, total RNA was extracted from frozen PBMCs
(5 × 106–107 cells) using a Qiagen RNeasy kit according to the
manufacturer’s protocol. Quality control of the isolated RNA was
performed using an Agilent bioanalyser and NanoDrop 8000
(Thermo Scientific). An OD260/280 ratio between 1.8 and 2.2 and
a RIN value above 9.0 was considered for further processing.
The RNA Pan-Cancer Immune Profiling Panel, which
includes 770 genes (109 cell surface markers for 24 immune
cell types, 30 cancer testis antigens, >500 immune response
genes, and 40 reference genes) was used. Briefly, 150 ng of
RNA was hybridized for 16 h using capture and reporter probes.
The samples were then immobilized into a cartridge using the
nCounterTM prep-station. Digital images were processed within
the nCounterTM Digital Analyser instrument, with 555 fields of
view (fov) being collected for each sample. The reporter probe
counts, i.e., the number of times the color-coded barcode for
that gene is detected, were tabulated in a comma separated value
(CSV) format for analysis using the nSolver
TM
package (version
3.0) and Advanced Analysis module (version 1.0.36). The QC,
normalization, differential expression and pathway analysis were
performed using the nSolver advance analysis module according
to the guidance given by manufacturers (12).
Principle component analysis (PCA) was used for
dimensionality reduction and for assessing sample grouping.
Genes with a false discovery rate below 0.05 were considered as
being significantly differentially expressed.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 6.0
software. Non-parametric unpaired t-test andMann-WhitneyU-
test were used to assess the significance of differences between
healthy controls and patients with breast cancer. A paired t-test
was used to determine the significance of differences between the
same patients before and after chemotherapy. A non-parametric
One-Way ANOVA and Kruskal-Wallis test were used when
assessing more than two groups of data. Multiple comparisons
were also made between the medians of each data set. For
all statistical comparisons, a p-value < 0.05 was considered to
represent statistically significant differences.
RESULTS
The underlying hypothesis of the study is that phenotypic
profiling and immune transcriptomic analyses of peripheral
blood cells reflect disease status in patients with breast cancer and
have the potential to inform clinical decisions and help predict
therapeutic response. We therefore investigated (1) whether the
peripheral blood immunome of breast cancer patients differs
from that of healthy controls; (2) whether chemotherapy affects
this immune phenotype; and (3) whether a defined peripheral
blood immune phenotypic profile relates to a specific molecular
breast cancer subgroup.
The Peripheral Blood Immunome of
Patients With Breast Cancer Displays a
More Suppressive Phenotype Than That of
Age-Matched Controls
The frequency and phenotype of T cells, B cells, monocyte subsets
and NK cells in the peripheral blood of 67 patients with breast
cancer and in 23 age/sex-matched healthy controls was assessed.
The clinical and biological characteristics of the patients are
shown in Table 1 (More details in Supplementary Table 1). The
majority of patients had luminal-A breast cancer (46 of 67) and
stage I-II disease (45 of 67).
The percentage of CD3+CD4+CD127negCD25+FoxP3+
Treg cells were significantly higher in patients with breast
cancer (Figure 1A) than in their no-known disease, age-
matched counterparts. We then focused on a more in-depth
characterization of Treg cell subsets. CD39 expression has
previously been shown to be restricted to a subset of FoxP3+
regulatory effector/memory-like T (TREM) cells, whereas ICOS
is a CD28-like co-stimulatory molecule which is expressed by
recently-activated T cells (13). We found that the proportion
of Treg cells expressing CD39 and ICOS, either alone or in
combination was the same in patients with breast cancer and
controls (Figures 1B,C,E). However, the proportion of Treg cells
lacking both CD39 and ICOS expression was higher in patients
compared to controls (Figure 1D).
Although there were no differences in the overall percentage
of all monocytes in the blood of patients and controls (data
not shown), more detailed analysis of monocyte subsets revealed
fewer classical monocytes (CD14++CD16neg), but significantly
more intermediate monocytes (CD14++/+CD16+) in patients
with breast cancer. No differences in the frequency of non-
classical monocytes (CD14+CD16++) in patients and controls
were observed (Figure 2A).
PBMCs were also stained with a cocktail of mAbs in
order to identify and enumerate MDSCs (antibody details
in Supplementary Table 2). Although no difference in the
overall frequency of CD11b+CD33+ within HLA-DRneg cells
was found (data not shown), a significantly higher percentage
of HLA-DRnegCD11b+CD33+ cells also expressing CD15+
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FIGURE 1 | There are significantly more Treg cells in the peripheral blood of patients with breast cancer and these exhibit an overall more activated/suppressive
phenotype: PBMCs from patients with breast cancer and individuals with no-known disease were rapidly defrosted, allowed to rest for 2 h at 37◦C, washed, and
incubated with an Fc blocking reagent before being stained with a cocktail of mAbs reactive with cell surface antigens. Intracellular staining was undertaken following
treatment with Fix/Perm and incubation with a FoxP3 mAb. Data were acquired on a Beckman Coulter GalliosTM flow cytometer and analyzed using Beckman Coulter
KaluzaTM software. A two-tailed Mann Whitney test was performed to determine any significant differences in the measured parameters between healthy individuals
and patients with breast cancer. A Wilcoxon matched-pairs two tailed test was used to assess the significance between Pre/Post-chemotherapy. A Kruskal-Wallis test
was used to assess the significance of any differences in the measured parameters between the different disease stages, and individuals with no-known disease (**P
< 0.005). There was a significantly higher number of CD3+CD4+CD127negCD25+FoxP3+ (regulatory T (Treg) cells) in the PBMCs of patients with breast cancer (A).
No differences were found between healthy controls and cancer patients for CD39neg/ICOSpos (B) or CD39pos/ICOSpos (C) or CD39pos/ICOSneg (E), however there
were significantly fewer CD39neg/ICOSneg Treg cells in the peripheral blood of patients with breast cancer (D).
was found in the PBMCs of patients with breast cancer
compared with controls (Figure 2B). MDSCs in the PBMCs
from patients with breast cancer were enriched in potentially
immunosuppressive arginase-1+ cells. These phenotypic
characteristics were consistent with the granulocytic nature of
the MDSCs. It has been suggested that granulocytic MDSCs
(HLA-DRnegCD11b+CD33+CD15+) should only be evaluated
in freshly isolated PBMCs (14). However, although some
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FIGURE 2 | Greater percentage of inflammatory monocytes and granulocytic MDSCs (gMDSCs) in the peripheral blood of patients with breast cancer than in
age-matched volunteers. PBMCs from patients with breast cancer and individuals with no-known disease were rapidly defrosted, allowed to rest for 2 h at 37◦C,
washed and then incubated with an Fc blocking reagent before being stained with a cocktail of mAbs reactive with cell surface antigens. Freshly isolated PBMCs from
a proportion of patients were then stained for the expression of intracellular Arginase. Data were acquired using a Beckman Coulter GalliosTM flow cytometer and
analyzed using Beckman Coulter Kaluza
TM
software. A two-tailed Mann Whitney test was performed to assess differences between patients with cancer and their
corresponding controls, and a Wilcoxon matched-pairs two tailed test was used to assess the influence of chemotherapy. A Kruskal-Wallis test was used to assess
the significance of any differences in the measured parameters between the different disease stages, and individuals with no-known disease (*P < 0.05; **P < 0.005;
***P < 0.0005). A significantly higher percentage of pro-inflammatory monocytes within the CD14+ population was present in the PBMCs from patients with breast
cancer (A). Although no difference was found in the proportion of CD11b+CD33+ within DRneg cells, a significantly higher percentage of DRnegCD11b+CD33+ cells
were CD15+ in patients with breast cancer (B). A significantly higher percentage of freshly isolated MDSCs from patients with breast cancer were Arginase+ cells, and
the percentage of Arginase+ MDSCs was positively associated with disease stage (B). Similar proportions of CD56dimCD16+ and CD56brightCD16− NK cells were
present in patients with breast cancer and healthy controls; however there were significant differences in the intensity of CD56 expression on both NK cell subsets (C).
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granulocytic MDSCs were lost during freezing/defrosting of
PBMC preparations (Supplementary Figure 1), the significantly
increased percentage of gMDSCs in the blood of patients with
breast cancer compared to healthy controls was maintained
(Supplementary Figure 1).
The percentage of NK cells and the proportion of the primary
NK cell subsets (CD56dimCD16+ and CD56brightCD16−) in
patients with breast cancer and controls were not significantly
different (Figure 2C). Further analysis of these cell subsets
revealed significant differences in themean fluorescence intensity
(MFI) of CD56 expression, with the intensity of CD56
expression being significantly higher on the CD56dimCD16+
subset (Figure 2C). The intensity of CD16 expression was the
same for both NK cell subsets. As NK cells express a variety of
inhibitory and activating receptors which are involved in target
recognition and killing, the expression levels of nine NK cell
receptors were determined in patients with breast cancer. The
expression of activating receptors NKp30, NKp46 and 2B4, as
detected by the increase in the MFI, was significantly decreased.
Although the proportion of NK cells expressing the inhibitory
receptor NKG2A was decreased, the intensity of NKG2A
expression on cells was increased (Supplementary Figure 2). It
is possible that the activity rather the proportion of NK cells is
affected by the presence of tumor, indeed, Konjevic´ et.al. found
that the activity of NK cells from patients with breast cancer
was significantly decreased and correlated with the spontaneous
release of LDH by the peripheral blood lymphocytes (PBL) of
patients with breast cancer in a stage-dependant manner (15).
Chemotherapy Significantly Decreases the
Absolute Number of B Cells
The quantification of helper T cells (CD3+CD4+), cytotoxic
T cells (CD3+CD8+), B cells (CD19+CD3neg), monocytes
(CD45+CD14+) and NK cells (CD16+/CD56+CD3neg) revealed
no significant differences between patients with breast cancer
and healthy controls (data not shown). Moreover, the overall
percentage of Treg cells, MDSCs and NK cells was not
significantly altered following chemotherapy (nor was the
relative distribution of the CD56dim and CD56bright subsets). In
contrast, a single round of neoadjuvant chemotherapy resulted
in significant changes in the MFI of certain NK cells markers.
Indeed, the intensity of CD56 expression on CD56dimCD16+
NK cells was significantly increased, as was the percentage of
NK cells expressing the activating receptor NKp44, the intensity
of expression (MFI) of activating receptors NKp30 and 2B4
and the expression (MFI) of the inhibitory receptors LAIR and
NKG2A. An increase in the percentage of the CD56bright subset of
NK cells expressing the inhibitory receptor CD85j, concomitant
with a decreased percentage of cells expressing the inhibitory
receptor DNAM-1 and the activating receptor NKp46 (although
the intensity of expression was also observed to increase on
positive cells) (Supplementary Figure 2).
The absolute number of classical monocytes (as assessed
by CD45+CD3negCD14+) was lower after chemotherapy
(Figure 3). A statistically significant decrease of B cells and an
increase of monocyte counts over baseline values was found after
neoadjuvant anthracycline treatment (Figures 3A,B), in line
with previous findings by Wijayahadi (16) and Verma (17).
The immune profile of the PBMCs isolated from the blood
of patients with breast cancer showed significant differences
compared to those isolated from the blood of healthy controls
and tended to increase with stage although this was not
statistically significant (Supplementary Figure 3).
We hypothesized that the lack of differences between
molecular subtypes observed might be caused by the limited
number of markers that had been used to characterize Treg cells,
and our focused immunophenotyping ofMDSCs, monocytes and
NK cells and that the assessment of a wider range of immune-
related genes would reveal differences between, at least, the most
clinically distinct breast cancer subgroups, i.e., luminal-A vs.
TNBC.
Identification of a 3-Gene Signature Which
Predicts Relapse in TNBC Treated With
Chemotherapy
The immune transcriptome from a subgroup of 23 randomly
selected patients, 14 with TNBC and 9 with luminal-A
breast cancer was profiled using the NanoString nCounterTM
platform. Overall, immune gene expression profiles in the
PBMCs of patients with TNBC and luminal-A breast cancer
were similar (Figure 4A). However, an unsupervised clustering
analysis revealed that three of the 14 patients with TNBC
exhibited distinct immune gene expression patterns (Figure 4A).
A list of the top 20 differentially expressed genes is shown
in Figures 4B,C. The gene sets that were up- or down-
regulated in these two subgroups of TNBC patients included
CD163 (a scavenger receptor involved in the resolution of
inflammation), cytokine receptors such as IFNGR1 (CD119),
IL21R, IL1R2, FLT3, IL1RAP, and TXNIP (which promotes anti-
inflammatory macrophages) and HMGB1 (which is upregulated
under inflammatory conditions) (Figures 4B,C). The top 20
differentially expressed genes were then further analyzed using
Metacore software (Supplementary Table 3). Eight of them
were found to be functionally related to the inflammation
pathway and their ability to predict clinical outcome (when
expressed in the tumors of patients) was analyzed in silico in
186 TNBC (basal) patients using the Kaplan-Meier-plotter on-
line tool (18). The analysis revealed that the combined low-
expression of CD163 and CXCR4 and the high expression
of THBS1 significantly correlated with having a high risk of
recurrence and poor survival rate in TNBC (basal), but not
in patients with either ER+ or HER+ disease (Figure 4E).
However, it should be note that these results were obtained using
unfractionated PBMCs which may have masked some immune
signature.
DISCUSSION
Herein, we report on the changes in the absolute number
of monocytes and B cells 2 weeks after the first cycle
of chemotherapy, on the increased percentage of immune
suppressive cells such as Treg cells MDSCs, and intermediate
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FIGURE 3 | Chemotherapy affects the absolute number of B cells and monocytes (A), but not the percentage of Treg cells, MDSCs and NK cells (B). Peripheral blood
(5–20mL) was collected into EDTA Vacutainers
TM
and processed within 2 h. An aliquot of whole blood was used to obtain T cell, B cell, monocyte and NK cell counts
using BD TrucountTM beads (BD Biosciences) following the manufacturers protocol. For this, 100µL of blood was mixed directly in the BD TrucountTM bead tube with
mAbs to CD3, CD8, CD4, CD19, CD56, CD45, and CD14. Tubes were incubated for 15min at room temperature, protected from light, after which erythrocytes were
lysed via a 15-min incubation at room temperature in BD Pharm LyseTM lysing solution. Cells were analyzed by flow cytometry within 1 h. No significant differences
were found in the number of the different immune cells between patients and healthy donors. B cells and monocytes were the only two cell types significantly affected
by one course of chemotherapy (A). A paired t-test was used to compare the samples. (*P < 0.05; **P < 0.005; ***P < 0.0005) and (C) PBMCs from patients with
breast cancer and individuals with no-known disease were rapidly defrosted, allowed to rest for 2 h at 37◦C, washed, and incubated with an Fc blocking reagent
before being stained with a cocktail of mAbs reactive with cell surface antigens. Intracellular staining was undertaken following treatment with Fix/Perm and incubation
with a FoxP3 mAb. Data were acquired using Beckman Coulter GalliosTM flow cytometer and analyzed using Beckman Coulter KaluzaTM software. A two-tailed Mann
Whitney test was performed to assess significant differences in the phenotypic profiles in patients with breast cancer and their corresponding controls, and a Wilcoxon
matched-pairs two tailed test was used to assess the influence of chemotherapy. A Kruskal-Wallis test was used to assess the significance of any differences in the
measured parameters between the different disease stages, and individuals with no-known disease (*P < 0.05; **P < 0.005; ***P < 0.0005). The percentage of Treg
cells was not affected by one round of chemotherapy (data not shown). The abosulte number of monocytes (CD45+CD3negCD14+) was found to be significantly
increased by chemotherapy (B) while that of B-cells (CD45+CD3negCD19+) was significantly decreased, whereas only the MFI of CD56dim NK cells was affected by
chemotherapy.
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FIGURE 4 | Peripheral blood mononuclear cells (PBMCs) from a distinct subgroup of patients with TNBC differentially expressed immune-related genes. Total RNA
was extracted from frozen PBMCs frozen PBMCs from 23 randomly selected patients, 14 with TNBC and 9 with luminal-A breast cancer (5 × 106 – 107 cells) using a
Qiagen RNAesasy kit according to the manufacturer’s instructions. Gene expression profiling was carried out using a NanoString nCounterTM FLEX platform
(NanoString Technologies Inc.). The Pan-Cancer Immune Profiling Panel was used to assess immune function at the mRNA level according to the manufacturer’s
protocol. Raw data were acquired using the nCounterTM digital analyser with 555 fields of view (fov) being collected for each sample. Differential expression and
further analysis was performed using Human PanCancer Immune Profiling Advanced Analysis (version 1.0.36). Principle component analysis (PCA) was used for
dimensionality reduction and assessing sample grouping. Genes with a false discovery rate below 0.05 were considered as significant. No differences in the mRNA
expression profiles in PBMCs from 9 patients with Luminal A disease and 11 of the patients with TNBC were observed. However, PBMCs from 3 out of the 14 patients
with TNBC demonstrated a clearly distinct immune gene expression profile (A). (B,C) Show the 20 top most differentially regulated genes between these two groups
[PBMCs from 11 patients with TNBC (TNBC1) and the 3 distinct TNBC (TNBC2)]. High expression of CD163 combined with high expression of CXCR4 and low
expression of THBS1 was associated with better RFS (p = 0.00012). Interestingly, this combination of genes was not associated with any difference in RFS for
patients with ER positive breast cancer (p = 0.7) (D).
monocytes as well as the increased expression of inhibitory
receptors on the surface of NK cells (as assessed by the
increase in MFI) in the PBMCs of 85 patients with breast
cancer (50 of which were evaluated both before and after
one cycle of anthracycline-based chemotherapy) and 23 control
volunteers. These immune cell types are known to contribute
to cancer-induced immune suppression and play a critical role
in sustaining cancer progression (8). Moreover, this study has,
for the first time, demonstrated that the assessment of 770
immune-related genes in PBMCs from patients with TNBC using
the NanoString nCounterTM amplification-free gene expression
profiling platform was able to highlight differences in a subset of
patients with TNBC which, if further validated in a prospective
study, could have extremely high clinical significance for the
management and treatment of TNBC. Indeed, monitoring the
expression of these 3-genes in patients with TNBC after standard
of care could anticipate those at high risk of relapsing who might
benefit from a vaccine intended to target any new emerging
cancer cells.
Our results reinforce and expand previous studies showing
significantly higher percentage of circulating Treg cells and
MDSCs in patients with breast cancer, and their association
with increased tumor burden (19, 20). Treg cells from the
patients evaluated in the study reported herein also displayed
a suppressive/activated phenotype compared with those from
healthy donors, as was indirectly indicated by the significant
decrease in the percentage of Treg cells lacking both ICOS
and CD39 expression. This observation suggests that the
proportion of ICOS−CD39− Treg cells may increase as the
disease progresses. Importantly, ICOS+FoxP3+ Treg cells use
IL-10 to suppress the function of dendritic cells (DCS) and TGF-
β to suppress T cell function, whereas the ICOS−FoxP3+ Treg
cells primarily employ TGF-β (21, 22). Other cytokines have
been shown to be involved in the suppression and progression of
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cancer, For example, levels of TNFa have been found to increase
with the clinical stage in multiple myeloma patients (23). In view
of these results, further studies should include additional Treg
markers in order to perform a more in depth anlaysis of these
cells in the PBMCs of patients with breast cancer, such as those
that have been performed by Miyara (24) or Kordasti (25).
In addition to the increased proportion of Treg cells, higher
numbers of MDSCs were present in patients with breast cancer,
and the percentage of these increased with disease stage,
albeit not significantly. This was in agreement with another
study which has recently reported on the presence of elevated
frequencies of CD14+HLA-DR−/low mMDSCs in early breast
cancer (26). Importantly, Bailur et al. demonstrated that the
ability of womenwithHER2+ breast cancer tomount an immune
response against the HER2 antigen was linked with low levels
of Lin−CD14+HLA-DR− MDSCs and Treg cells, and that this
was associated with a 100% 5-year survival rate compared to
only 38% for those who had no detectable level of Her2-
reactive CD8+ T cells, but had high frequencies of MDSCs
(27). In addition, a study in 17 patients with early stage breast
cancer receiving doxorubicin–cyclophosphamide chemotherapy
found a correlation between circulating MDSCs, clinical stage,
chemotherapy treatment and metastatic tumor burden Gonda
et al. (28). A more recent study, (29) found that MDSC levels
were increased in pre-operative breast cancer patients, but
decreased following removal of their tumor. More importantly,
the proportion of MDSCs increased following recurrence.
Furthermore, MDSC levels in patients with recurrent breast
cancer have been found to decrease following chemotherapy (29).
Immunotherapeutic approaches using IL-2 and agonistic CD40
antibodies have been shown to effectively remove both Treg cells
and MDSCs. These strategies should be considered prior to, or in
combination with, active immunotherapy as ameans of depleting
immune suppressive cell types, thus favoring durable anti-tumor
responses (30).
The expansion of distinct monocyte subsets having a unique
phenotype and function has been associated with cardiovascular
diseases, inflammation, cancer and the administration of growth
factors (31). Moreover, elderly, frail patients with breast cancer
who experience unexpected hospitalization after chemotherapy
treatment exhibit higher levels of granulocytic cells (CD15+),
but lower levels of cells with suppressor phenotypes, including
CD14−CD15+CD124+ MDSCs and Treg cells, at baseline
(32). Herein, we have found a significantly higher number
of CD14++/+CD16+ intermediate monocytes in patients with
breast cancer. Interestingly, CD14+CD16+ monocytes have been
proposed to be an early indicator of breast cancer (33).
We also found that chemotherapy significantly decreased
the absolute number of B cells, whereas the percentages of
suppressive cells such as Treg cells andMDSCs were not affected.
This is of particular importance for future immunotherapeutic
interventions in patients undergoing chemotherapy, since not
only do B cell numbers decrease significantly, as reported by
Verma et al. (19), but they remain significantly depleted even 9
months after chemotherapy. Furthermore, their phenotype also
remains significantly different from those that were present prior
to chemotherapy.
The importance of NK cells in the manifestation of protective
anti-tumor immunity is increasingly evident. In mouse models
of breast cancer, NOD/SCID/γcnull mice (those which lack
T, B, and NK cells) implanted with human MDA-MB-231
(triple negative) breast cancer cells exhibited primary tumor
formation followed by the formation of metastases about
3 weeks later (34). However, similar experiments conducted
in NOD/SCID mice (which possess NK cells) result in
smaller primary tumors, but metastatic spread. In a large-
scale prospective study in Japan, the cytotoxic activity of
NK cells was assessed in 3625 volunteers who were then
monitored for cancer development during the following 11 years.
Intriguingly, individuals with low NK cell activity at baseline
were significantly more susceptible to the development of cancer
(35).
The triggering of NK cells by target cells involves a
balance between signals from activating and inhibitory receptors.
Although previous studies have shown that the expression of
some NK cell receptors (NKG2D, NKp30, DNAM-1, CD16,
and 2B4) may be low in patients with breast cancer (36),
the prognostic or diagnostic value of this information remains
unclear. Furthermore, although neoadjuvant therapy reduces
NK cell numbers (17), little is known about its effect on the
expression of NK cell activating and inhibitory receptors. The
effect of chemotherapeutic treatments on the expression of NK
cell receptors has not been widely studied in patients with
breast cancer. Previous reports have shown that the density of
expression of NK cell activating and cytotoxicity receptors, e.g.,
NKG2D, NKp30, DNAM-1, CD16, and 2B4, may be reduced
in patients compared with healthy volunteers (36). In this
study, patients displayed significantly reduced expression of the
activating receptors NKp30, NKp46, and 2B4, in addition to a
significant reduction in expression of the inhibitory receptors
NKG2A.
Immune gene expression profiling studies showed that
PBMCs from patients with Luminal A disease were not
significantly different to those from patients with TNBC. These
findings confirmed our flow cytometry data which showed that
the more immune-suppressive phenotype observed was disease-
related rather than molecular sub-type specific. Interestingly, the
concept that the immune phenotype, whether in the periphery
or in the tumor microenvironment, correlates more closely
with the severity of the disease rather than the breast cancer
molecular subtypes has also recently been described by Savas
et al. (37) who found that the overall percentage of CD45+
TILs did not change according to each breast cancer subtype
(TNBC, HER2+, and hormone receptor–positive (luminal)), but
was significantly higher in primary than in metastatic tumor
samples. In our study, we have found that the transcriptome
of PBMCs from 3 of the 14 patients with TNBC which were
analyzed showed a significant difference in the expression of
genes mostly related to inflammation which, after in silico
analysis, was reduced to 3 genes (CD163, CXCR4, THBS1).
Subsequent analysis using a publicly-available dataset revealed
that the coordinated low-expression of CD163 and CXCR4 with
high expression of THBS1 in 161 breast cancer tissues identified
patients with TNBC (basal) having a high risk of recurrence
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and poor survival rate. We are now pursuing the validation of
this signature in the PBMCs and tissue of the same patients
in order to find out whether these genes can be used as a
blood-based surrogate of the tumor immune microenvironment
and be used to identify patients at risk of recurrence after
chemotherapy. However, it should be noted that because the
NanoString profiling was perfomed using unfractionated PBMCs
this might have masked specific immune signature from immune
cell subtype and future studies will need to profile isolated cell
sub-populations.
In summary, this study has demonstrated that the peripheral
blood immunome in patients with breast cancer exhibits a more
immunosuppressive phenotype than that of healthy controls,
and that this is more associated with the disease stage than
the ER status. Interrogation of the peripheral blood at the
cellular and transcriptional level has the potential to provide
insight into the presence and stage of disease. Moreover,
although the ability of transcripts for CD163/CXCR4 and
THBS1 in PBMCs to predict intra-tumoral expression remains
to be demonstrated, this novel immune signature could prove
extremely important in the monitoring of patients with TNBC.
It is indeed conceivable that minimally-invasive analyses of
immune gene transcripts in the blood will inform clinical
decisions, including the potential use of immunomodulatory
agents.
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Supplementary Figure 1 | Despite the significant loss of gMDSCs after
defrosting, significant differences in the percentage of CD15+ cells within the
DRnegCD11b+CD33+ population between healthy controls and patients is
retained. PBMCs from patients with breast cancer and individuals with no-known
disease were rapidly defrosted, allowed to rest for 2 h at 37◦C, washed and then
incubated with an Fc blocking reagent before being stained with a cocktail of
mAbs reactive with cell surface antigens. Alternatively, freshly isolated PBMCs
from a proportion of patients and healthy individuals were stained using a cocktail
of mAbs that define MDSCs. Data were acquired using a Beckman Coulter
Gallios
TM
flow cytometer and analyzed using Beckman Coulter Kaluza
TM
software. A two-tailed Mann Whitney test was performed to assess differences
between patients with cancer and their corresponding controls, and a Wilcoxon
matched-pairs two-tailed test was used to assess the influence of chemotherapy.
A Kruskal-Wallis test was used to assess the significance of any differences in the
measured parameters between the different disease stages, and individuals with
no-known disease (∗P < 0.05; ∗∗P < 0.005; ∗∗∗P < 0.0005). The majority of
granulocytic MDSCs (DRnegCD11b+CD33+CD15+) did not survive the
freezing/defrosting procedure (Figure 1A). However, the significantly higher
percentage of CD15+ cells within the DRnegCD11b+CD33+ population in the
PBMCs from patients with breast cancer (compared with PBMCs from
age-matched controls) remained apparent in the defrosted PBMCs (Figure 1B),
with a significantly higher proportion being apparent in the early stages of disease
(Stage1) (Figure 1C).
Supplementary Figure 2 | NK cell subsets in the periphery of healthy controls
and patients with breast cancer (A), and in patients with breast cancer after one
round of chemotherapy (B). Similar proportions of CD56dimCD16+ and
CD56brightCD16− NK cells were present in patients with breast cancer and
healthy controls (A). Chemotherapy had no effect on the intensity of CD16
expression (B).
Supplementary Figure 3 | The percentage of immunosuppressive immune cells
increases with tumor stage. PBMCs from patients with breast cancer and
individuals with no-known disease were rapidly defrosted, allowed to rest for 2 h at
37◦C, washed and then incubated with an Fc blocking reagent before being
stained with a cocktail of mAbs reactive with cell surface antigens. Data were
acquired using a Beckman Coulter Gallios
TM
flow cytometer and analyzed using
Beckman Coulter Kaluza
TM
software. A two-tailed Mann–Whitney test was
performed to assess differences between patients with cancer and their
corresponding controls, and a Wilcoxon matched-pairs two-tailed test was used
to assess the influence of chemotherapy. A Kruskal–Wallis test was used to
assess the significance of any differences in the measured parameters between
the different disease stages, and individuals with no-known disease (∗P < 0.05;
∗∗P < 0.005; ∗∗∗P < 0.0005). Significant differences in the percentage of (A) Treg,
(B) classical (CD14++CD16neg), or (C) intermediate (CD14++/+CD16+)
monocyte subtypes and the percentage of (D) MDSCs (DRnegCD11b+CD33+
CD15+) were primarily found between healthy controls and patients with cancer,
rather than between difference molecular subtypes of cancer. However, the
majority of patients had luminal disease. Consequently, a subsequent analysis was
performed on patients diagnosed with Luminal A only and those with a higher
stage disease tended to have less Treg CD39+/ICOS+, less classical monocytes,
and more intermediate monocytes and more gMDSCs.
Supplementary Table 1 | Patient demographics and summary of flow cytometric
analysis.
Supplementary Table 2 | Antibody panels used in this study.
Supplementary Table 3 | Identification of an immune gene signature predicting
high risk of relapse and poor survival in TNBC. The 20 most differentially regulated
genes identified by the nSolver software package (Nanostring Technologies) were
assessed by Metacore, the results of which are shown here (Table 3).
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